16234-14-3

Basic information

• Product Name: 2,4-Dichlorothieno[3,2-d]pyrimidine
• Synonyms: Thieno[3,2-d]pyrimidine, 2,4-dichloro-;2,4-Dichlorothiopheno[3,2-d]pyrimidine;2,4-dichlorothieno[3,2-d]pyrimidine ,97%;2,4-dichlorothieno[3,2-d]...;4-dichlorothieno[3;2,4-dichlorothieno;2,4-dichlorothieno[3,2-d]pgriMidine;2,4-Dichlorothieno[3,2-d]pyrimidine
• CAS NO: 16234-14-3
• Molecular Formula: C₆H₂Cl₂N₂S
• Molecular Weight: 205.06448
• EINECS: 1312995-182-4
• Product Categories: Heterocycles;API intermediates;CHIRAL CHEMICALS;Heterocycle-Pyrimidine series
• Mol File: 16234-14-3.mol
• Article Data: 77

Chemical Properties

• Melting Point: 136.0 to 140.0 °C
• Boiling Point: 274.804 °C at 760 mmHg
• Flash Point: 119.997 °C
• Appearance: /
• Density: 1.662 g/cm³
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: -0.72±0.40(Predicted)
• CAS DataBase Reference: 2,4-Dichlorothieno[3,2-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Dichlorothieno[3,2-d]pyrimidine(16234-14-3)
• EPA Substance Registry System: 2,4-Dichlorothieno[3,2-d]pyrimidine(16234-14-3)

Safety Data

• Safety Statements: 24/25
• RIDADR: UN2811
• HazardClass: IRRITANT
• Hazardous Substances Data: 16234-14-3(Hazardous Substances Data)

Usage

Chemical Properties

2,4-Dichlorothieno[3,2-d]pyrimidine is White solid

Uses

2,4-Dichlorothieno[3,2-d]pyrimidine is used in the synthesis of PI3K inhibitor under noncryogenic conditions.

Upstream product

• 16233-51-5 1H-thieno[3,2-d]pyrimidine-2,4-dione 
• 51322-68-0 methyl 3-[(aminocarbonyl)amino]-2-thiophenecarboxylate 
• 22288-78-4 Methyl 3-aminothiophene-2-carboxylate 
• 57-13-6 urea 
• 16233-51-5 2,4-dihydroxythieno[3,2-d]pyrimidine 
• 16233-51-5 thienoyleneurea 

Downstream Products

• 152943-20-9 2-(3,4-Dimethoxyphenethylamino)-4-(1,2,3,4-tetrahydro-6,7-dimethoxyisoquinol-2-yl)thieno[3,2-d]pyrimidine hydrochloride 
• 16234-15-4 2-chloro-4-morpholinothieno[3,2-d]pyrimidine 
• 1024603-85-7 4-((2-chlorothiophene[3,2-d]pyrimidin-4-yl)oxy)-3,5-dimethylbenzonitrile 
• 1024603-87-9 2-chloro-N-mesitylthieno[3,2-d]pyrimidin-4-amine 
• 1024603-84-6 2-chloro-4-(mesityloxy)thieno[3,2-d]pyrimidine 
• 1144081-74-2 2-chloro-4-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-thieno[3,2-d]pyrimidine 
• 1002726-48-8 C₁₃H₁₀ClN₃OS 
• 1235451-09-8 2-chloro-N-phenylthieno[3,2-d]pyrimidine-4-amine 
• 885698-98-6 4-(6-(bromomethyl)-2-chlorothieno[3,2-d]pyrimidin-4-yl)morpholine 
• 885675-66-1 4-(2-chloro-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno[3,2-d]-pyrimidin-4-yl)morpholine 
• 1235450-27-7 Ethyl 2-((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methylamino)pyrimidine-5-carboxylate 
• 1235450-94-8 methyl 2-(((2-(4-(aminomethyl)phenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxylate 
• 1235450-97-1 methyl 2-(((2-(3-(aminomethyl)phenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxylate 
• 1235451-07-6 ethyl 2-(((2-(4-aminophenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxylate 

Relevant articles and documents

PARP-1/PI3K double-target inhibitor or pharmaceutically acceptable salt thereof, preparation method and application thereof

The invention discloses a PARP-1/PI3K double-target inhibitor or a pharmaceutically acceptable salt thereof, a preparation method and application thereof. According to the invention, the single active component can play a dual inhibition role on PARP-1 and PI3K, so that the dosage is reduced, the treatment effect is improved, and the toxic and side effects are reduced; and the dual inhibition effect on PARP-1 and PI3K is significant, the IC50 value of each target does not exceed 1.0 [mu]M, and the drug using the PARP-1/PI3K double-target inhibitor as the active component can be used for treating a variety of cancers or tumors related to PARP-1 and/or PI3K.

Discovery of an Orally Active and Long-Acting DPP-IV Inhibitor through Property-Based Optimization with an in Silico Biotransformation Prediction Tool

Long-acting dipeptidyl peptidase IV inhibitors have emerged as promising molecules for interventions for type 2 diabetes. Once weekly dosing brings greater patient compliance and more stable glycemic control. Starting from our previous highly potent compound with a thienoprimidine scaffold, which is unfortunately severely hit by hepatic biotransformation, a lead compound was rapidly generated by drawing on the experience of our previously discovered long-acting compounds with pyrrolopyrimidine scaffold. With the aid of an in silico biotransformation prediction tool, (R)-2-((2-(3-aminopiperidin-1-yl)-4-oxo-6-(pyridin-3-yl)thieno[3,2-d]pyrimidin-3(4H)-yl)methyl)-4-fluorobenzonitrile was eventually generated and determined to have high potency, a fine pharmacokinetic profile, and a long-acting in vivo efficacy.

Design, synthesis and biological evaluation of novel 2,4-bismorpholinothieno[3,2-d]pyrimidine and 2-morpholinothieno[3,2-d]pyrimidinone derivatives as potent antitumor agents

To develop novel therapeutic agents with anticancer activities, two series of novel 2,4-bismorpholinyl-thieno[3,2-d]pyrimidine and 2-morpholinothieno[3,2-d]pyrimidinone derivatives were designed, synthesized and evaluated for their biological activities. Among them, compound A12 showed the most potent antitumor activities against HCT116, PC-3, MCF-7, A549 and MDA-MB-231 cell lines with IC50 values of 3.24 μM, 14.37 μM, 7.39 μM, 7.10 μM, and 16.85 μM, respectively. Further explorations in bioactivity were conducted to clarify the anticancer mechanism of compound A12. The results showed that compound A12 obviously inhibited the proliferation of A549 cell lines and decreased mitochondrial membrane potential, which led to the apoptosis of cancer cells and suppressed the migration of tumor cells.